KYTX — Kyverna Therapeutics Share Price
0.000.00%
Last trade - 00:00- $98.54m
- -$186.52m
- 38
- 51
- 14
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.37 | ||
| Price to Tang. Book | 0.37 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.64% | ||
| Return on Equity | -80.74% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.66 | 7.03 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 14th, 2018
- Public Since
- February 8th, 2024
- No. of Shareholders
- 28
- No. of Employees
- 112
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 43,218,873
- Address
- 5980 Horton Street, Suite 550, EMERYVILLE, 94608
- Web
- https://kyvernatx.com/
- Phone
- +1 5106268331
- Auditors
- BDO USA, P.C.
Upcoming Events for KYTX
Kyverna Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Kyverna Therapeutics Inc Earnings Release
Similar to KYTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Kyverna Therapeutics share price?
As of Today at 21:42 UTC, shares in Kyverna Therapeutics are trading at $2.28. This share price information is delayed by 15 minutes.
How has the Kyverna Therapeutics share price performed this year?
Shares in Kyverna Therapeutics last closed at $2.28 and the price had moved by -84.83% over the past 365 days. In terms of relative price strength the Kyverna Therapeutics share price has underperformed the S&P500 Index by -86.32% over the past year.
What are the analyst and broker recommendations for Kyverna Therapeutics?
The overall consensus recommendation for Kyverna Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kyverna Therapeutics dividend yield?
Kyverna Therapeutics does not currently pay a dividend.
Does Kyverna Therapeutics pay a dividend?
Kyverna Therapeutics does not currently pay a dividend.
When does Kyverna Therapeutics next pay dividends?
Kyverna Therapeutics does not currently pay a dividend.
How do I buy Kyverna Therapeutics shares?
To buy shares in Kyverna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kyverna Therapeutics?
As of the previous close price of $2.28, shares in Kyverna Therapeutics had a market capitalisation of $98.54m.
Where are Kyverna Therapeutics shares listed?
Here are the trading details for Kyverna Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KYTX
What kind of share is Kyverna Therapeutics?
Based on an overall assessment of its quality, value and momentum Kyverna Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kyverna Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Kyverna Therapeutics is $17.00. That is 645.61% above the last closing price of $2.28.
Analysts covering Kyverna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.89 for the next financial year.
Find out moreWhat is the trend in the Kyverna Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kyverna Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -53.16%.
As of the last closing price of $2.28, shares in Kyverna Therapeutics were trading -50.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kyverna Therapeutics PE Ratio?
The Kyverna Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kyverna Therapeutics?
We do not have data on Kyverna Therapeutics' directors